학술논문

Spectrum and Frequency of Germline FANCM Protein-Truncating Variants in 44,803 European Female Breast Cancer Cases
Document Type
article
Author
Gisella FiglioliAmandine BillaudQin WangManjeet K. BollaJoe DennisMichael LushAnders KvistMuriel A. AdankThomas U. AhearnNatalia N. AntonenkovaPäivi AuvinenSabine BehrensMarina BermishevaNatalia V. BogdanovaStig E. BojesenBernardo BonanniThomas BrüningNicola J. CampArchie CampbellJose E. CastelaoMelissa H. CessnaNBCS CollaboratorsKamila CzenePeter DevileeThilo DörkMikael ErikssonPeter A. FaschingHenrik FlygerMarike GabrielsonManuela Gago-DominguezMontserrat García-ClosasGord GlendonEncarna B. Gómez GarciaAnna González-NeiraFelix GrassmannPascal GuénelEric HahnenUte HamannPeter HillemannsMaartje J. HooningReiner HoppeAnthony HowellKeith HumphreyskConFab InvestigatorsAnna JakubowskaElza K. KhusnutdinovaVessela N. KristensenAnnika LindblomMaria A. LoizidouJan LubińskiArto MannermaaTabea MaurerDimitrios MavroudisWilliam G. NewmanNadia ObiMihalis I. PanayiotidisPaolo RadiceMuhammad U. RashidValerie RheniusMatthias RuebnerEmmanouil SaloustrosElinor J. SawyerMarjanka K. SchmidtRita K. SchmutzlerMitul ShahMelissa C. SoutheyIan TomlinsonThérèse TruongElke M. van VeenCamilla WendtXiaohong R. YangKyriaki MichailidouAlison M. DunningPaul D. P. PharoahDouglas F. EastonIrene L. AndrulisD. Gareth EvansAntoinette HollestelleJenny Chang-ClaudeRoger L. MilnePaolo Peterlongo
Source
Cancers, Vol 15, Iss 13, p 3313 (2023)
Subject
breast cancer predisposition
breast cancer risk factors
FANCM PTVs spectrum
protein truncating variants
PTVs
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Language
English
ISSN
2072-6694
01386115
Abstract
FANCM germline protein truncating variants (PTVs) are moderate-risk factors for ER-negative breast cancer. We previously described the spectrum of FANCM PTVs in 114 European breast cancer cases. In the present, larger cohort, we report the spectrum and frequency of four common and 62 rare FANCM PTVs found in 274 carriers detected among 44,803 breast cancer cases. We confirmed that p.Gln1701* was the most common PTV in Northern Europe with lower frequencies in Southern Europe. In contrast, p.Gly1906Alafs*12 was the most common PTV in Southern Europe with decreasing frequencies in Central and Northern Europe. We verified that p.Arg658* was prevalent in Central Europe and had highest frequencies in Eastern Europe. We also confirmed that the fourth most common PTV, p.Gln498Thrfs*7, might be a founder variant from Lithuania. Based on the frequency distribution of the carriers of rare PTVs, we showed that the FANCM PTVs spectra in Southwestern and Central Europe were much more heterogeneous than those from Northeastern Europe. These findings will inform the development of more efficient FANCM genetic testing strategies for breast cancer cases from specific European populations.